<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273818</url>
  </required_header>
  <id_info>
    <org_study_id>FC-001</org_study_id>
    <nct_id>NCT01273818</nct_id>
  </id_info>
  <brief_title>Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair</brief_title>
  <official_title>Is Topical Antibiotic Prophylaxis Effective in Lichtenstein Hernia Repair: a Comparison Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to measure the effectiveness of topical gentamicin to prevent
      post-operative infection in inguinal tension-free hernia repair operation.Secondary aim is,
      if it is effective as a prophylactic agent, to compare it's effect with intra venous single
      dose cefazolin sodium prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single blind prospective randomized trial. To measure and compare the
      effectiveness intra-operative topical gentamicin application in tension-free inguinal hernia
      repair in contrast to intravenous peri-operative prophylactic cefazolin sodium and
      combination of gentamicin and cephazolin this study is designed.

      The patients are grouped randomly in to two groups:

        -  Group1;intravenous cefazolin sodium

        -  Group2;topical gentamicin

        -  Group3:topical gentamicin and intravenous cefazolin sodium

      As a control group we decided to use the data of control groups ( without any prophylactic
      agent usage ) of previous studies done in our clinic and medical data base reviews.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Post-operative Infection</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infections in Each Study Arm</measure>
    <time_frame>within the 30 days after surgery</time_frame>
    <description>Patients were examined on postoperative 30 days for the presence of surgical site infection.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>gentamicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 mg gentamicin topical application intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of 1000 mg cefazolin intra venously 1 hour before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gentamicin and cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin and cefazolin</intervention_name>
    <description>80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation</description>
    <arm_group_label>gentamicin and cefazolin</arm_group_label>
    <other_name>Drug: Cefazolin</other_name>
    <other_name>Other names:</other_name>
    <other_name>Cezol</other_name>
    <other_name>Eqizolin</other_name>
    <other_name>Drug: Gentamicin</other_name>
    <other_name>Gensif</other_name>
    <other_name>Gentamed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>1000 mg cefazolin application intravenously 1 hour before operation</description>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>Cezal</other_name>
    <other_name>Eqizolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>80 mg gentamicin application intraoperatively</description>
    <arm_group_label>gentamicin</arm_group_label>
    <other_name>Gensif</other_name>
    <other_name>Gentamed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of inguinal hernia

        Exclusion Criteria:

          -  Femoral hernia

          -  Emergency cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaye E Seker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diskapi Yildirim Beyazit Teaching and research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duray Seker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Diskapi Yildirim Beyazit Teaching and research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bahattin Bayar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Diskapi Yildirim Beyazit Teaching and research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zafer Ergul, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Diskapi Yildirim Beyazit Teaching and research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakan Kulacoglu, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Diskapi Yildirim Beyazit Teaching and research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit Teaching and research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Pessaux P, Lermite E, Blezel E, Msika S, Hay JM, Flamant Y, Deepak V, Arnaud JP; French Associations for Surgical Research. Predictive risk score for infection after inguinal hernia repair. Am J Surg. 2006 Aug;192(2):165-71.</citation>
    <PMID>16860624</PMID>
  </reference>
  <reference>
    <citation>Tzovaras G, Delikoukos S, Christodoulides G, Spyridakis M, Mantzos F, Tepetes K, Athanassiou E, Hatzitheofilou C. The role of antibiotic prophylaxis in elective tension-free mesh inguinal hernia repair: results of a single-centre prospective randomised trial. Int J Clin Pract. 2007 Feb;61(2):236-9.</citation>
    <PMID>16930145</PMID>
  </reference>
  <reference>
    <citation>Zuvela M, Milićević M, Galun D, Lekić N, Basarić D, Tomić D, Petrović M, Palibrk I. [Infection in hernia surgery]. Acta Chir Iugosl. 2005;52(1):9-26. Review. Serbian.</citation>
    <PMID>16119310</PMID>
  </reference>
  <reference>
    <citation>Praveen S, Rohaizak M. Local antibiotics are equivalent to intravenous antibiotics in the prevention of superficial wound infection in inguinal hernioplasty. Asian J Surg. 2009 Jan;32(1):59-63. doi: 10.1016/S1015-9584(09)60011-7.</citation>
    <PMID>19321405</PMID>
  </reference>
  <reference>
    <citation>Aufenacker TJ, Koelemay MJ, Gouma DJ, Simons MP. Systematic review and meta-analysis of the effectiveness of antibiotic prophylaxis in prevention of wound infection after mesh repair of abdominal wall hernia. Br J Surg. 2006 Jan;93(1):5-10. Review.</citation>
    <PMID>16252314</PMID>
  </reference>
  <reference>
    <citation>Shankar VG, Srinivasan K, Sistla SC, Jagdish S. Prophylactic antibiotics in open mesh repair of inguinal hernia - a randomized controlled trial. Int J Surg. 2010;8(6):444-7. doi: 10.1016/j.ijsu.2010.05.011. Epub 2010 Jun 9.</citation>
    <PMID>20538079</PMID>
  </reference>
  <reference>
    <citation>Aufenacker TJ, van Geldere D, van Mesdag T, Bossers AN, Dekker B, Scheijde E, van Nieuwenhuizen R, Hiemstra E, Maduro JH, Juttmann JW, Hofstede D, van Der Linden CT, Gouma DJ, Simons MP. The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. Ann Surg. 2004 Dec;240(6):955-60; discussion 960-1.</citation>
    <PMID>15570201</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2014</results_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Teaching and Research Hospital</investigator_affiliation>
    <investigator_full_name>Duray Seker</investigator_full_name>
    <investigator_title>M.D. Surgery</investigator_title>
  </responsible_party>
  <keyword>inguinal hernia</keyword>
  <keyword>infection prophylaxis</keyword>
  <keyword>topical gentamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period begins in Jan 2011. This period will be completed when record of minimum number participants ( according to power analysis) in each arm is completed.Location is surgery clinic of our hospital.</recruitment_details>
      <pre_assignment_details>Totaly, 24 patients who were known using any kind of antibiotics for any reason just prior to surgery or just after the surgery and having history of allergic reactions to antibiotics used in this study were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gentamicin</title>
          <description>Gentamicin arm: application of 80 mg gentamycin topically</description>
        </group>
        <group group_id="P2">
          <title>Cefazolin</title>
          <description>Application of 1000 mg cefazolin sodium intra venously 1 hour before surgery</description>
        </group>
        <group group_id="P3">
          <title>Gentamicin+ Cefazolin Sodium</title>
          <description>Application of intravenous 1000 mg cefazolin sodium 1 hour before surgery + topical 80 mg gentamicin intraoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>300 consequtive patients were diveded into three groups randomly, but during follow-up period since 24 patients used any kind of antibiotics for reasons other than postoperative complications, only 276 patients were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>Gentamicin</title>
          <description>Gentamicin arm: application of 80 mg gentamycin topically</description>
        </group>
        <group group_id="B2">
          <title>Cephazolin</title>
          <description>Application of 1000 mg cefazolin sodium intra venously 1 hour before surgery</description>
        </group>
        <group group_id="B3">
          <title>Gentamicin+ Cefazolin Sodium</title>
          <description>Application of intravenous 1000 mg cefazolin sodium 1 hour before surgery + topical 80 mg gentamicin intraoperatively</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="91"/>
            <count group_id="B4" value="276"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.39" spread="15.39"/>
                    <measurement group_id="B2" value="49.60" spread="13.85"/>
                    <measurement group_id="B3" value="50.36" spread="15.49"/>
                    <measurement group_id="B4" value="50.10" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Post-operative Infection</title>
        <time_frame>within the first 30 days after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infections in Each Study Arm</title>
        <description>Patients were examined on postoperative 30 days for the presence of surgical site infection.</description>
        <time_frame>within the 30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Gentamicin</title>
            <description>Total number of patients to which topical gentamicin was applied for prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Cefazolin IV</title>
            <description>Total number of patients to which ceephazoline (İV) was applied for prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>Topical and iv</title>
            <description>Total number of patients to which topical gentamicin and cephazoline (iv) was applied for prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infections in Each Study Arm</title>
          <description>Patients were examined on postoperative 30 days for the presence of surgical site infection.</description>
          <units>infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: our primary outcome is “infection positive or negative”so, we compared the frequencies of being positive infections for these three groups. Our null hypothesis is “ positive infection frequencies are same for three groups”. We calculated post-hoc power for this design and found 0.99 for the percentages which shows positive infections respectively for Topical Gentamicin, cefazoline iv and topical gentamicin and iv cefazolin; 2.3%, 3.1% and 0%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gentamicin</title>
          <description>Gentamicin arm: application of 80 mg gentamycin topically
Gentamicins+cephazolin sodium: 80 mg topically, intra-operative,single dose
No adverse effect</description>
        </group>
        <group group_id="E2">
          <title>Cephazolin</title>
          <description>Application of 1000 mg cefazolin sodium intra venously 1 hour before surgery
Gentamicins+cephazolin sodium: 80 mg topically, intra-operative,single dose
No adverse effect</description>
        </group>
        <group group_id="E3">
          <title>Gentamicin+ Cefazolin Sodium</title>
          <description>Application of intravenous 1000 mg cefazolin sodium 1 hour before surgery + topical 80 mg gentamicin intraoperatively
Gentamicins+cephazolin sodium: 80 mg topically, intra-operative,single dose
No adverse effect</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Gaye Seker</name_or_title>
      <organization>S.B.Ankara Diskapi Yildirim Beyazit Education and Teaching Hospital</organization>
      <phone>+905323360618</phone>
      <email>gayeebru@superonline.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

